Decoding West Pharmaceutical Services Inc (WST): A Strategic SWOT Insight
Unraveling the Financial and Strategic Position of WST Post Q1 2024 Results
Stay updated with breaking news from Proprietary Product. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Unraveling the Financial and Strategic Position of WST Post Q1 2024 Results
West Pharmaceutical Services, Inc. (NYSE: WST) reported first-quarter 2024 adjusted earnings per share (ETF:EPS) of $1.56, which beat the Zacks Consensus Estimate by 20.9%. The bottom line, however, was down 21.2% year over year.
Robust Revenue Growth and Strategic Focus Propel Alkermes Into 2024
/PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2023 and updated full-year 2023...
Quintin Lai: …conference call. We issued our financial results this morning, and the release has been posted in the Investors section on the company's website located at westpharma.com.